Aldebaran Financial’s iShares Biotechnology ETF IBB Stock Holding History

Aldebaran Financial’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,250	Closed	-$293K	–	85
2022 Q1	$293K	Sell	2,250 -200	-8%	-$26.1K	0.23%	73
2021 Q4	$374K	Hold	2,450	–	–	0.28%	64
2021 Q3	$396K	Hold	2,450	–	–	0.32%	58
2021 Q2	$402K	Hold	2,450	–	–	0.33%	57
2021 Q1	$369K	Hold	2,450	–	–	0.33%	61
2020 Q4	$371K	Hold	2,450	–	–	0.35%	57
2020 Q3	$332K	Hold	2,450	–	–	0.35%	57
2020 Q2	$335K	Hold	2,450	–	–	0.39%	60
2020 Q1	$264K	Hold	2,450	–	–	0.26%	77
2019 Q4	$295K	Hold	2,450	–	–	0.22%	81
2019 Q3	$240K	Hold	2,450	–	–	0.16%	86
2019 Q2	$267K	Hold	2,450	–	–	0.18%	88
2019 Q1	$274K	Hold	2,450	–	–	0.19%	89
2018 Q4	$236K	Hold	2,450	–	–	0.18%	91
2018 Q3	$299K	Hold	2,450	–	–	0.19%	87
2018 Q2	$269K	Buy	2,450 +200	+9%	+$21.4K	0.18%	89
2018 Q1	$240K	Hold	2,250	–	–	0.16%	92
2017 Q4	$240K	Hold	2,250	–	–	0.16%	90
2017 Q3	$250K	Hold	2,250	–	–	0.17%	88
2017 Q2	$233K	Buy	+2,250	New	+$222K	0.17%	90

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Aldebaran Financial's IBB Position: Q2 2022 in Review

Aldebaran Financial sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 2,250 shares — an estimated $293K sold.

Aldebaran Financial first reported a position in IBB in Q2 2017 and held it in 20 quarters. The position peaked at $402K in Q2 2021. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

Aldebaran Financial reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
Aldebaran Financial sold 2,250 iShares Biotechnology ETF shares in Q2 2022, an estimated $293K.
Aldebaran Financial first reported a position in iShares Biotechnology ETF in Q2 2017 and held it in 20 quarters.
Aldebaran Financial's iShares Biotechnology ETF position peaked at $402K in Q2 2021.
858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on Aldebaran Financial's 13F filing for Q2 2022, filed 1 Aug 2022.